潰瘍性大腸炎(UC)治療薬のパイプライン分析

P&S Market Researchが発行した調査報告書(PSM802162)
◆英語タイトル:Ulcerative Colitis Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration and Other Developments
◆商品コード:PSM802162
◆発行会社(リサーチ会社):P&S Market Research
◆発行日:2017年4月1日
◆ページ数:174
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Group License(5名様閲覧用)USD3,250 ⇒換算¥367,250見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD7,000 ⇒換算¥791,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はP&S Market Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。P&S Market Research社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

According to a new research report “Ulcerative Colitis Therapeutics Pipeline Analysis, 2017 – Clinical Trials & Results, Patent, Designation, Collaboration and Other Developments” published by P&S Market Research, ulcerative colitis currently exhibits a strong pipeline with approximately 89 drug candidates.
Ulcerative Colitis Pipeline Analysis

The ulcerative colitis pipeline analysis report covers approximately 89 drug candidates in different stages of development.

Ulcerative colitis is a chronic inflammatory disease, which basically affect colonic mucosa. The main identified symptoms of the disease are bloody diarrhea, abdominal cramps and fatigue. Some of the other symptoms include, fever, vomiting, anorexia, abdominal distension and bloating. The treatment approaches to this disease mostly include the use of small molecules and monoclonal antibodies, which are being developed to target and reduce the inflammatory mediators.

Pipeline Insights

The pipeline for ulcerative colitis was analyzed based on route of administration, it was found that most of the drug candidates are being developed to be administered by oral route.

Major companies collaborate for the development of ulcerative colitis pipeline

The research found that different companies are engaged in the collaboration for ulcerative colitis. In June, 2015 Lycera Corp. and Celgene Corporation collaborated for the development of Lycera Corp. drug candidate for the treatment of ulcerative colitis. Celgene obtained the exclusive right to acquire Lycera upon conclusion of the option period or achievement by Lycera of pre-specified clinical milestones. During the option period, Lycera retained full control of its research and development programs.

Novel and patented technologies for ulcerative colitis pipeline

The novel technologies are being used for ulcerative colitis drug candidates. Protalix Ltd. is using ProCellEx technology platform for their drug candidates. ProCellEx technology platform overcomes the weaknesses by offering significant production, regulatory and cost benefits.

Some of the key players developing ulcerative colitis therapeutics include EA Pharma Co., Ltd., Celgene Corporation, InDex Pharmaceuticals AB and others.

【レポートの目次】

Chapter 1. Research Background

1.1. Research Objectives

1.2. Definition

1.3. Research Scope

1.3.1. Pipeline Analysis by Phase

1.3.2. Pipeline Analysis by Route of Administration

1.3.3. Pipeline Analysis by Molecule Type

1.4. Key Stakeholders

Chapter 2. Research Methodology

2.1. Secondary Research

2.2. Primary Research

2.2.1. Breakdown of Primary Research Respondents

2.2.1.1. By industry participants

2.2.1.2. By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1. Ulcerative Colitis Therapeutics Overview

4.1.1. Signs and Symptoms

4.1.2. Pathophysiology

4.1.3. Diagnosis

4.1.4. Treatment

4.1.5. Epidemiology

4.2. Key Drivers

4.3. Key Barriers

4.4. Ulcerative Colitis Therapeutics Pipeline Analysis

4.4.1. Pipeline Analysis by Phase

4.4.2. Pipeline Analysis by Molecule Type

4.4.3. Pipeline Analysis by Route of Administration

4.4.4. Pipeline Analysis by Company

Chapter 5. Ulcerative Colitis Therapeutics Pipeline Analysis by Phase (2017)

5.1. Pre-registration/Registration: Drug Profiles

5.1.1. Pre-Clinical Studies

5.1.2. Clinical Trials

5.1.3. Clinical Results

5.1.4. Strategic Developments

5.1.5. Designations

5.1.6. Grants

5.1.7. Patents

5.1.8. Technology

5.2. Phase III: Drug Profiles

5.2.1. Pre-Clinical Studies

5.2.2. Clinical Trials

5.2.3. Clinical Results

5.2.4. Strategic Developments

5.2.5. Designations

5.2.6. Grants

5.2.7. Patents

5.2.8. Technology

5.3. Phase II: Drug Profiles

5.3.1. Pre-Clinical Studies

5.3.2. Clinical Trials

5.3.3. Clinical Results

5.3.4. Strategic Developments

5.3.5. Designations

5.3.6. Grants

5.3.7. Patents

5.3.8. Technology

5.4. Phase I: Drug Profiles

5.4.1. Pre-Clinical Studies

5.4.2. Clinical Trials

5.4.3. Clinical Results

5.4.4. Strategic Developments

5.4.5. Designations

5.4.6. Grants

5.4.7. Patents

5.4.8. Technology

5.5. Pre-Clinical: Drug Profiles

5.5.1. Pre-Clinical Studies

5.5.2. Strategic Developments

5.5.3. Designations

5.5.4. Grants

5.5.5. Patents

5.5.6. Technology

5.6. Discovery: Drug Profiles

5.6.1. Strategic Developments

5.6.2. Designations

5.6.3. Grants

5.6.4. Patents

5.6.5. Technology

5.7. Inactive: Drug Profiles

5.7.1. Pre-Clinical Studies

5.7.2. Clinical Trials

5.7.3. Clinical Results

5.7.4. Strategic Developments

5.7.5. Designations

5.7.6. Grants

5.7.7. Patents

5.7.8. Technology

5.8. Discontinued: Drug Profiles

5.8.1. Pre-Clinical Studies

5.8.2. Clinical Trials

5.8.3. Clinical Results

5.8.4. Strategic Developments

5.8.5. Designations

5.8.6. Grants

5.8.7. Patents

5.8.8. Technology

Chapter 6. Clinical Trials Analysis

6.1. Clinical Trials by Region

6.2. Clinical Trials by Trial Status

Chapter 7. Competitive Landscape Analysis

7.1. Key Players Benchmarking

7.2. SWOT Analysis

Chapter 8. Company Profiles

8.1 Business Overview

8.2 Product and Service Offerings

Chapter 9. Appendix

9.1 Abbreviations

Note: Certain sections of the above table of contents would vary according to the availability of information.



【レポートのキーワード】

潰瘍性大腸炎(UC)

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 潰瘍性大腸炎(UC)治療薬のパイプライン分析(Ulcerative Colitis Therapeutics Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration and Other Developments)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆